The therapeutic community is abuzz with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 target that’s exhibiting significant promise in clinical trials for managing obesity. Unlike some available weight loss solutions, retatrutide appears to provide a more substantial reduction in body weight and improve metabolic health, particu